Raymond James Initiates Coverage On Oncolytics Biotech with Outperform Rating, Announces Price Target of $3
Portfolio Pulse from Benzinga Newsdesk
Raymond James analyst Rahul Sarugaser has initiated coverage on Oncolytics Biotech (NASDAQ:ONCY) with an Outperform rating and set a price target of $3. This new coverage could influence investor sentiment and potentially impact the stock's short-term performance.
April 04, 2024 | 5:47 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Raymond James initiated coverage on Oncolytics Biotech with an Outperform rating and a price target of $3, indicating a positive outlook for the stock.
The initiation of coverage by a reputable analyst firm like Raymond James with an Outperform rating and a specific price target provides a positive signal to the market, potentially increasing investor confidence and demand for ONCY shares in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100